Goldridge Terminal 로고 Goldridge Terminal
인기
로그인

관심목록에 추가
Pro 차트

Anteris Technologies Glob...

NasdaqGM: AVR · 실시간 가격 · USD
8.87
-0.30 (-3.27%)
종가 기준: Aug 12, 2026, 3:59 PM

Anteris Technologies Global Corp. (AVR) Stock Price, Analysis & Data

-3.27%
매수호가5.95
시가총액864.46M
매출 (ttm)1.85M
순이익 (ttm)-95.3M
베타0.73
EPS (ttm)-1.88
P/E (ttm)n/a
선행 P/E-9.05
P/B (ttm)3.10
P/S (ttm)466.46
Earnings DateNov 12, 2026
매도호가10.57
거래량817,451
평균 거래량 (20일)1,295,824
시가9.03
전일 종가9.17
일중 범위8.59 - 9.09
52주 범위3.30 - 11.05
애널리스트n/a
목표주가15 (69.11%)
배당n/a
배당락일n/a

AVR 소개

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification prepa...

[더 보기]
산업 Medical Instruments & Supplies
섹터 Healthcare
IPO 일자 Dec 13, 2024
직원 수 174
상장 거래소 NasdaqGM
티커 AVR
웹사이트 https://anteristech.com
전체 기업 정보

재무 실적

2023년 Anteris Global의 매출은 2.73M로, 전년 3.2M 대비 -14.56% 감소했습니다. 순이익은 -46.02M로, 50.58% 증가했습니다.

재무제표

애널리스트 전망

애널리스트 3명의 투자의견을 종합하면 AVR 주식의 평균 등급은 "null"입니다. 12개월 목표주가는 15로, 최근 주가 대비 69.11% 상승 여력입니다.

주가 전망

어닝 서프라이즈

Anteris Global가 Aug 11, 2026에 분기 실적을 발표했습니다:
  • 매출 n/a 예상치 하회 $0, 및 NaN% 전년 대비 성장.
  • EPS -0.3 예상치 하회 -0.09, 및 50.82% 전년 대비 성장.

    • 다음 실적 발표

    Anteris Technologies Global Corp.의 실적 발표 예정일은 Nov 12, 2026, 정규장 중입니다.
    애널리스트 예상 매출은 ... 업그레이드
    news image

    1일 전 · Proactive

    Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway

    Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) made progress on its pivotal PARADIGM Trial during the June quarter, enrolling and treating its first US patients after securing Medicare reimburseme...

    news image

    2개월 전 · Proactive

    France clearance marks key milestone for Anteris' pivotal PARADIGM Trial

    Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has secured full regulatory clearance from France's National Agency for Medicines and Health Products Safety (ANSM) for its global pivotal PARADIGM T...

    news image

    3개월 전 · Simply Wall St.

    Here's Why We're Not Too Worried About Anteris Technologies Global's (ASX:AVR) Cash Burn Situation

    We can readily understand why investors are attracted to unprofitable companies. For example, although...

    news image

    3개월 전 · Proactive

    Anteris adds Susan Knight, Stephen Denaro to board as company advances heart valve strategy

    Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has strengthened its board with the appointments of experienced healthcare and finance executive Susan Knight and company veteran Stephen Denaro as d...

    news image

    3개월 전 · Proactive

    Anteris advances PARADIGM trial as Q1 cash burn reflects commercialisation push

    Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has reported strong operational progress for the March 2026 quarter as the company advanced recruitment for its global PARADIGM pivotal trial and str...

    2 페이지 중 1